Table 1.
Serum anti-SARS-CoV-2 IgG neutralizing antibodies (NAb) in Autoimmune Systemic Diseases (ASD).at different time points.
| Pts no. | After vaccination (A) |
After 6 months (B) |
After booster (C) |
P | |
|---|---|---|---|---|---|
| Diseases | NAb titer BAU/mL, mean (SEM) | NAb titer BAU/mL, mean (SEM) | NAb titer BAU/mL, mean (SEM) | ||
| RA | 48 | 334,8 (±98,92) | 194,0 (±61,04) | 1444 (±136,9) | A vs B ns B vs C < 0.0001 A vs C < 0.0001 |
| SLE | 16 | 570,3 (±172,8) | 146,2 (±70,94) | 1785 (±255,7) | A vs B < 0.05 B vs C < 0.0001 A vs C < 0.0001 |
| SSc | 153 | 812,7 (±65,11) | 479,8 (±59,95) | 1528 (±99,28) | A vs B < 0.0001 B vs C < 0.0001 A vs C < 0.0001 |
| CV | 21 | 783,8 (±236,8) | 97,54 (±29,21) | 1442 (±241) | A vs B < 0.05 B vs C < 0.05 A vs C < 0.0001 |
| Other Vasculitis | 4 | 193,6 (±65,93) | 676,6 (±607,9) | 1349 (±406,3) | A vs B ns B vs C ns A vs C ns |
| ASD total∗ | 244 | 696,8 (±52,68) | 370,8 (±41,92) | 1527 (±74,16) | A vs B < 0.0001 B vs C < 0.0001 A vs C < 0.0001 |
| Controls | 502 | 1138 (±46,93) | 643.9 (±26.84) | 2470 (±10.74) | A vs B < 0.0001 B vs C < 0.0001 A vs C < 0.0001 |
| Compared to Controls: | Compared to Controls: | Compared to Controls: | |||
| ASD (p. <0.0001) | ASD (p. <0.0001) | ASD (p. <0.0001) | |||
| RA (p. <0.0001); SLE (p. 0,0023) | RA (p. <0,0001); SLE (p. <0,0001) | RA (p. <0,0001); SLE (p. <0,0001) | |||
| SSc (p. <0,0001); CV (p. 0,0028) | SSc (p. <0,0001); CV (p. <0,0001) | SSc (p. <0,0001); CV (p. <0,0001) |
RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, SSc: systemic sclerosis, CV: cryoglobulinemic vasculitis.
A, B, and C: time 1, 2, and 3, respectively (see text).
*The group of 244 ASD patients who received either the first cycle and the booster dose of COVID-19 vaccine.